SPY389.63+0.17 0.04%
DIA312.42-0.01 0.00%
IXIC11,354.62-33.88 -0.30%

BRIEF-AstraZeneca Q1 Revenue $11.39 Bln, Maintains FY2022 Guidance

reuters.com · 04/29/2022 02:12
BRIEF-AstraZeneca Q1 Revenue $11.39 Bln, Maintains FY2022 Guidance

- AstraZeneca PLC AZN:

  • ASTRAZENECA PLC - FIRST QUARTER 2022 RESULTS

  • ASTRAZENECA PLC - Q1 REVENUE ROSE 60 PERCENT TO 11.39 BILLION USD

  • ASTRAZENECA - FY 2022 GUIDANCE AT CER REITERATED

  • ASTRAZENECA: 2022 HAS STARTED STRONGLY FOR ASTRAZENECA

  • ASTRAZENECA - QTRLY CORE EPS INCREASED 20% TO $1.89

  • ASTRAZENECA: UNVEILED PLANS FOR A NEW STRATEGIC RESEARCH AND DEVELOPMENT CENTRE IN HEART OF CAMBRIDGE, MASSACHUSETTS' SCIENTIFIC HUB

  • ASTRAZENECA - IN FY 2022 TOTAL REVENUE IS EXPECTED TO INCREASE BY A HIGH TEENS PERCENTAGE

  • ASTRAZENECA - QTRLY REPORTED EPS $0.25

  • ASTRAZENECA - IN FY 2022 CORE EPS IS EXPECTED TO INCREASE BY A MID-TO-HIGH TWENTIES PERCENTAGE

  • ASTRAZENECA - EMERGING MARKETS TOTAL REVENUE, INCLUDING CHINA, IS EXPECTED TO GROW MID-SINGLE-DIGITS IN FY 2022

  • ASTRAZENECA - IN FY 2022 TOTAL REVENUE FROM COVID-19 MEDICINES IS ANTICIPATED TO DECLINE BY A LOW-TO-MID TWENTIES PERCENTAGE

  • ASTRAZENECA - CHINA TOTAL REVENUE IS EXPECTED TO DECLINE BY A MID-SINGLE-DIGIT PERCENTAGE IN FY 2022

  • ASTRAZENECA: MAJORITY OF VAXZEVRIA REVENUE FROM INITIAL CONTRACTS, SEVERAL OF WHICH COMPLETED DURING THE QUARTER

  • ASTRAZENECA - MAJORITY OF VAXZEVRIA REVENUE IN 2022 IS EXPECTED TO COME FROM INITIAL CONTRACTS

  • ASTRAZENECA - EXPECTED DECLINE IN SALES OF VAXZEVRIA BEING PARTIALLY OFFSET BY GROWTH IN EVUSHELD SALES

  • ASTRAZENECA: ACTIVELY MANAGE HEIGHTENED RISKS FROM COVID-19, GEOPOLITICAL, SUPPLY CHAIN UNCERTAINTIES; VARIATIONS IN PERFORMANCE BETWEEN QTRS EXPECTED TO CONTINUE

  • ASTRAZENECA - IN FY 2022 GROSS MARGIN FROM COVID-19 MEDICINES IS EXPECTED TO BE LOWER THAN COMPANY AVERAGE

  • ASTRAZENECA: $1,145M REVENUES FROM VAXZEVRIA AND $469M FROM EVUSHELD IN QUARTER

  • ASTRAZENECA - IS UNABLE TO PROVIDE GUIDANCE ON A REPORTED BASIS BECAUSE CO CANNOT RELIABLY FORECAST MATERIAL ELEMENTS OF REPORTED RESULT

  • ASTRAZENECA: THERE ARE NO MATERIAL ACCOUNTING IMPACTS ARISING FROM RUSSIA-UKRAINE CONFLICT IMPACTING OUR Q1 2022 REPORTING

Source text for Eikon: ID:nRSc7840Ja

Further company coverage: AZN


((Reuters.Briefs@thomsonreuters.com;;))